A Khavinson tripeptide (Glu-Asp-Arg) marketed for brain tissue — short cycles for cognitive maintenance and neuroprotection. Khavinson-lineage data, limited independent replication.
Pinealon is a short synthetic tripeptide (Glu-Asp-Arg) from the Khavinson bioregulator family, marketed for brain tissue. Like other Khavinson peptides (Epitalon for pineal, Cartalax for cartilage, Testagen for testes, Prostamax for prostate), it works at very low doses in short cycles. The proposed mechanism is gene-expression modulation in target tissue based on molecular docking + nuclear penetration + sequence preference; in-cell promoter occupancy in vivo has not been independently mapped.
Used for cognitive maintenance, neuroprotection, and age-related mental decline. Russian clinical use dates to the 1990s; Western exposure is primarily through the research-peptide community.
Not FDA approved. Sold in Russia as a биологически активная добавка (БАД, dietary supplement) — not as a registered pharmaceutical. Not specifically named on the WADA 2026 Prohibited List, but the S0 catch-all for non-approved substances may apply at WADA's discretion. Available as oral capsule or injectable.
Per Khavinson's framework, short peptides interact with specific DNA regions relevant to their target tissue. Published mechanistic work documents molecular docking, nuclear penetration, and sequence preference — but in-cell promoter occupancy in vivo has not been independently mapped. The "modulates genes involved in neuronal metabolism / oxidative-stress defense / synaptic plasticity" framing is mechanistic inference from the docking and animal-model data, not direct in-cell evidence.
Preclinical data shows Pinealon reduces ischemia-reperfusion injury in rodent models, supporting the neuroprotective claim that drives most clinical use.
Used in Russian longevity programs alongside Epitalon (pineal) as a brain-targeted maintenance component.
| Benefit | Evidence |
|---|---|
| Cognitive function | Russian cohort studies in elderly: modest improvements in memory and attention |
| Neuroprotection | Preclinical models of ischemia and neurotoxicity |
| Stroke recovery adjunct | Russian clinical use; Western validation limited |
| Anti-aging maintenance | Paired with other bioregulators for systemic maintenance |
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeLike other Khavinson bioregulators, expect subtle, accumulating effects rather than acute changes. Most users don’t notice much on a single cycle. Note: SubQ administration is common in peptide-community use but is not documented in the published Pinealon literature — treat it as an empirical route, not a validated one. The upper end of the 400 mcg/day range is similarly extrapolated beyond the 200 mcg/day documented in PMID 22708445.
Clean safety profile in Russian clinical use. Side effects are rare.
Pre-filled with a typical Pinealon setup. Edit any field — the draw updates live.
Insulin syringe — 100 units = 1 mL
Free account. Saves your reconstitution + schedules doses + tracks every vial.
Dosing cheat sheet, reconstitution reference, and cycle planning — delivered to your inbox.
Pinealon is a research peptide not approved by the FDA for human use. It is sold only as a research chemical, and StackTrax does not endorse or facilitate personal use.
Quality varies enormously among research-chemical suppliers. At minimum, look for:
StackTrax’s preferred partner NextGen Peptides does not currently carry Pinealonin their catalog, which is why you don’t see a direct purchase link here. Other major research-chemical suppliers carry it; we don’t specifically recommend one for this compound.
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreePinealon is a short synthetic tripeptide (Glu-Asp-Arg) from the Khavinson bioregulator family, marketed for brain tissue. Like other Khavinson peptides (Epitalon for pineal, Cartalax for cartilage, Testagen for testes), it is used at very low doses in short cycles. It is positioned for cognitive maintenance, neuroprotection, and age-related mental decline. Russian clinical use dates to the 1990s; Western exposure is primarily through the research-peptide community.
No. Pinealon is not FDA approved. It is sold in Russia as a биологически активная добавка (dietary supplement), not as a registered pharmaceutical. It is not specifically named on the WADA 2026 Prohibited List, but the S0 catch-all for non-approved substances may apply at WADA's discretion. Available as oral capsule or injectable.
Per Khavinson's framework, short peptides interact with specific DNA regions in target tissue. Published mechanistic work documents molecular docking, nuclear penetration, and sequence preference, but in-cell promoter occupancy in vivo has not been independently mapped. The framing that it modulates genes involved in neuronal metabolism, oxidative-stress defense, and synaptic plasticity is mechanistic inference from docking and animal-model data rather than direct in-cell evidence. Preclinical data shows Pinealon reduces ischemia-reperfusion injury in rodent models.
Standard cycle is 100 to 200 mcg/day for 10 to 20 days, run 2 to 4 cycles per year. The literature-supported route is oral capsule (PMID 22708445 used 100 mcg twice daily, totaling 200 mcg/day). The up-to-400 mcg/day range that circulates in community protocols is extrapolated beyond what is documented in published clinical use. SubQ administration is common in the peptide community but is not documented in the published Pinealon literature, so treat it as an empirical route rather than a validated one.
Pinealon's clinical track record is built on Russian cohort studies in elderly patients showing modest improvements in memory and attention, plus Russian clinical use as a stroke recovery adjunct. Western independent replication is limited. Like other Khavinson bioregulators, expect subtle, accumulating effects rather than acute changes, and most users don't notice much on a single cycle.
Russian clinical use shows a clean safety profile and side effects are rare. The most common reports are mild GI discomfort (oral) and injection site reactions (SubQ). Use caution with pregnancy or breastfeeding, active brain tumor, and in children. One notable preclinical signal: PMID 21809624 reports Pinealon moderately raised caspase-3 activity (a marker of apoptosis) in rat brain tissue in a sham-operated control and a carotid occlusion model. The clinical significance in humans is unclear, but the finding is worth noting for a compound marketed as purely neuroprotective.
Disclaimer: This guide is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. The compounds discussed are not FDA approved for human use. Always consult a qualified healthcare provider before starting any new supplement or peptide protocol. StackTrax does not sell peptides or supplements directly — purchase links go to third-party vendors. StackTrax is not responsible for the products, quality, or business practices of any third-party vendor. This page contains affiliate links — StackTrax may earn a commission on purchases at no extra cost to you.
© 2026 StackTrax, LLC. All rights reserved.
StackTrax guides cover peptides and compounds that are not FDA-approved for the uses discussed. The dosing, reconstitution, and safety information is compiled from published research and community protocols for educational purposes only.
Before using any compound mentioned here, consult a qualified healthcare provider. StackTrax does not sell, prescribe, or recommend these substances for personal use.
These pages also contain affiliate links. We may earn a commission on purchases at no extra cost to you — this never changes our editorial recommendations.